Physician profile
Brian E Mathie
NPI 1013953116
$68,291.14
in general payments reported to CMS, 2019-2025
29 companies · $13K in 2025
The $13K reported for 2025 was more than what 99% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,530 · 2020: $389 · 2021: $7,241 · 2022: $22K · 2023: $16K · 2024: $4,499 · 2025: $13K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $15K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $7,875 · Food and Beverage: $5,096 · Travel and Lodging: $4,088 · Consulting Fee: $1,800.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $14,737.50 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $7,875.00 |
| Food and Beverage | $5,096.41 |
| Travel and Lodging | $4,087.87 |
| Consulting Fee | $1,800.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $52,778.95 | 2019-2025 | Cequa, Xelpros |
| Biotissue Holdings INC. | $5,977.45 | 2019-2025 | |
| Allergan, INC. | $2,877.42 | 2019-2022 | |
| Alcon Vision LLC | $1,034.18 | 2020-2025 | Hydrus Microstent, Tryptyr, Precision7 |
| Kala Pharmaceuticals, INC. | $933.62 | 2021-2022 | |
| Ivantis, INC | $655.37 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $644.26 | 2019-2023 | |
| Bausch & Lomb Americas INC. | $625.79 | 2023-2025 | Miebo, Infuse, Xiidra |
| Abbvie INC. | $573.68 | 2022-2025 | |
| Oyster Point Pharma, INC. | $401.19 | 2022-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Coopervision INC. | $300.35 | 2022-2025 | Misight Contact Lens |
| Aerie Pharmaceuticals, INC. | $263.16 | 2019-2021 | |
| Shire North American Group INC | $176.51 | 2019 | |
| Amgen INC. | $145.64 | 2024-2025 | Tepezza |
| Harrow Eye, LLC | $142.46 | 2024-2025 | Vevye, Iheezo |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dompe US, INC. | $138.57 | 2023-2024 | Oxervate |
| Tarsus Pharmaceuticals, INC. | $112.82 | 2024-2025 | Xdemvy |
| Thea Pharma INC. | $79.03 | 2022-2025 | Iyuzeh |
| Johnson & Johnson Vision Care, INC. | $68.89 | 2023 | Acuvue |
| Mallinckrodt Hospital Products INC. | $67.91 | 2020-2024 | Acthar |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $62.41 | 2019-2021 | |
| Astellas Pharma US INC | $47.35 | 2024 | Izervay |
| Rayner Intraocular Lenses Limited | $47.10 | 2022-2024 | Omidria |
| Carl Zeiss Meditec, INC. | $38.46 | 2019 | |
| Glaukos Corporation | $29.80 | 2023 | |
| Johnson & Johnson Surgical Vision, INC. | $28.63 | 2023-2024 | Tecnis Iol, Tecnis Iol |
| Rxsight INC | $18.69 | 2024 | Light Adjustable Lens (Lal), Rxsight Contact Lens, Rxsight Injector Cartridge |
| New World Medical,INC. | $11.05 | 2022 | |
| Maculogix, INC. | $10.40 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Mathie listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.